Building a supply chain including a domestic biosimilar manufacturing facility
First written in FY2025. 6 of 9 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-08-13.
0 other companies' latest entry also says "Restated".
- FY2026AdvancedAnnual report
「In November of the same year, based on an agreement concluded by the 4 companies, comprising the 3 companies and MBI, an important stakeholder in the support program, the Company established Alfenax Biologics Co., Ltd. (Alfenax Biologics) and began construction of a manufacturing facility on the premises of Alfresa Fine Chemical Co., Ltd., a subsidiary of Alfresa Holdings.」
The initiative to build a domestic biosimilar supply chain progressed to the establishment of Alfenax Biologics by the 4 companies and the start of construction of a manufacturing facility. - FY2026-H1AdvancedAnnual report
「In October 2025, as part of establishing the foundation for advancing this grant-funded project, the Company reached a basic agreement on a framework premised on establishing a joint venture to provide contract development and manufacturing services (CDMO) for biosimilars and other products and constructing a manufacturing facility on the premises of Alfresa Fine Chemical Co., Ltd., a subsidiary of Alfresa Holdings.」
The initiative to build a domestic supply chain through the 4 companies progressed to a basic agreement premised on establishing a CDMO joint venture and constructing a manufacturing facility on the premises of Alfresa Fine Chemical. - FY2025First statedAnnual report
「Following its selection for the grant in May 2025, the Company will work with 4 companies to advance the biosimilars business, including the development of facilities at candidate sites in Japan for manufacturing biosimilar active pharmaceutical ingredients and drug products, which is the objective of the grant-funded project.」
Following its selection for the Ministry of Health, Labour and Welfare's support program for developing domestic manufacturing facilities, the theme of building a domestic supply chain, including facilities for manufacturing biosimilar active pharmaceutical ingredients and drug products, was presented independently for the first time by Alfresa Holdings, Chiome, MBI and the Company.